We are live on
!
Find out more
N
Nuveen Portfolio holdings
AUM
$369B
1-Year Est. Return
31.66%
This Fund
S&P 500
This Quarter
Est. Return
-2.85%
1 Year Est. Return
+31.66%
3 Year Est. Return
+110.02%
5 Year Est. Return
+148.02%
10 Year Est. Return
+492.84%
AUM
$247B
AUM Growth
-$11.7B
(-4.5%)
Cap. Flow
-$1.08B
Cap. Flow
% of AUM
-0.44%
Top 10 Holdings %
Top 10 Hldgs %
21.96%
Holding
3,327
New
107
Increased
1,095
Reduced
1,938
Closed
58
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$3.11B |
| 2 |
iShares Russell 1000 Growth ETF
IWF
|
+$300M |
| 3 |
Baxter International
BAX
|
+$237M |
| 4 |
American Tower
AMT
|
+$196M |
| 5 |
UnitedHealth
UNH
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$343M |
| 2 |
Meta Platforms (Facebook)
META
|
+$300M |
| 3 |
Microsoft
MSFT
|
+$294M |
| 4 |
Salesforce
CRM
|
+$266M |
| 5 |
Match Group
MTCH
|
+$248M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.83% |
| 2 | Healthcare | 15.1% |
| 3 | Financials | 12.26% |
| 4 | Consumer Discretionary | 11.08% |
| 5 | Industrials | 8.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2051
Enanta Pharmaceuticals
ENTA
$400M
| $3.66M | ﹤0.01% |
70,475
-1,543
| -2% | -$90.1K |
|
2052
AMERISAFE
AMSF
$540M
| $3.65M | ﹤0.01% |
78,130
-1,908
| -2% | -$92.2K |
|
2053
Allegiant Air
ALGT
$2.57B
| $3.64M | ﹤0.01% |
49,890
-779
| -2% | -$80.5K |
|
|
PAYA
2054
DELISTED
Paya Holdings Inc. Class A Common Stock
PAYA
| $3.63M | ﹤0.01% |
593,790
+66,148
| +13% | +$435K |
|
2055
CoreCivic
CXW
$3.19B
| $3.62M | ﹤0.01% |
409,630
-14,283
| -3% | -$144K |
|
2056
Clearfield
CLFD
$374M
| $3.61M | ﹤0.01% |
34,541
-265
| -0.8% | -$25.8K |
|
2057
Buckle
BKE
$2.37B
| $3.61M | ﹤0.01% |
114,110
-18,468
| -14% | -$580K |
|
2058
Wolverine World Wide
WWW
$1.55B
| $3.61M | ﹤0.01% |
234,684
-7,313
| -3% | -$151K |
|
2059
Heritage Financial
HFWA
$1.21B
| $3.6M | ﹤0.01% |
136,206
-3,526
| -3% | -$93K |
|
|
HSKA
2060
DELISTED
Heska Corp
HSKA
| $3.59M | ﹤0.01% |
49,264
-21,505
| -30% | -$1.9M |
|
2061
Emergent Biosolutions
EBS
$248M
| $3.59M | ﹤0.01% |
170,976
-2,064
| -1% | -$57.4K |
|
|
VRE
2062
DELISTED
Veris Residential
VRE
| $3.59M | ﹤0.01% |
315,370
-39,105
| -11% | -$525K |
|
2063
Regenxbio
RGNX
$708M
| $3.58M | ﹤0.01% |
135,367
-3,988
| -3% | -$118K |
|
|
ACCD
2064
DELISTED
Accolade Inc
ACCD
| $3.58M | ﹤0.01% |
313,251
+3,813
| +1% | +$41.6K |
|
2065
Mirion Technologies
MIR
$3.91B
| $3.57M | ﹤0.01% |
477,991
-12,156
| -2% | -$85.6K |
|
|
PTRA
2066
DELISTED
Proterra Inc. Common Stock
PTRA
| $3.56M | ﹤0.01% |
714,147
-13,897
| -2% | -$77.9K |
|
2067
Hillman Solutions
HLMN
$1.79B
| $3.56M | ﹤0.01% |
471,644
-9,421
| -2% | -$83K |
|
2068
Lemonade
LMND
$4.1B
| $3.55M | ﹤0.01% |
167,773
+8,243
| +5% | +$187K |
|
2069
Core & Main
CNM
$8.71B
| $3.55M | ﹤0.01% |
156,203
-4,633
| -3% | -$108K |
|
2070
Tompkins Financial
TMP
$1.42B
| $3.55M | ﹤0.01% |
48,881
-2,156
| -4% | -$161K |
|
2071
Reynolds Consumer Products
REYN
$5.59B
| $3.55M | ﹤0.01% |
136,420
-3,837
| -3% | -$108K |
|
2072
Fastly Inc
FSLY
$3.66B
| $3.54M | ﹤0.01% |
386,258
-8,319
| -2% | -$88.6K |
|
2073
Adtran
ADTN
$616M
| $3.53M | ﹤0.01% |
182,718
+28,768
| +19% | +$628K |
|
2074
Fulgent Genetics
FLGT
$527M
| $3.53M | ﹤0.01% |
92,607
-133,345
| -59% | -$6.68M |
|
2075
C4 Therapeutics
CCCC
$412M
| $3.52M | ﹤0.01% |
401,884
-6,175
| -2% | -$64.1K |
|
Similar funds
VFT
Nuveen's Q3 2022 Portfolio in Review
As of Q3 2022, Nuveen held 3,327 positions worth $247B, down 4.5% from $259B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Trading was light in Q3 2022: portfolio turnover was 5%. Nuveen opened 107 new positions and exited 58, leaving the 3,327-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 24% a quarter earlier, followed by Healthcare and Financials.
- Nuveen's largest Q3 2022 buy was Alibaba: 1,014,906 shares worth $81.2M.
- Nuveen added most to Alnylam Pharmaceuticals in Q3 2022, an estimated $3.11B increase.
- Nuveen's biggest Q3 2022 reduction was Alphabet (Google) Class A, cutting an estimated $343M.
- Nuveen fully exited Atlassian in Q3 2022, selling an estimated $82.9M.
- Nuveen's ten largest holdings make up 22% of its $247B portfolio in Q3 2022.
- Nuveen opened 107 new positions and closed 58 in Q3 2022.
- Nuveen's portfolio value fell 4.5% quarter-over-quarter to $247B.
Based on Nuveen's 13F filing for Q3 2022, filed 14 Nov 2022.